- Home
- ETY vs ADRX Comparison
ETY vs ADRX Comparison
Compare ETY & ADRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ETY | ADRX |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2005 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ETY | ADRX |
|---|---|---|
| Price | $13.67 | $16.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $34.25 |
| AVG Volume (30 Days) | 310.6K | ★ 429.1K |
| Earning Date | 01-01-0001 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $72.35 |
| Revenue Next Year | N/A | $570.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.12 | $16.61 |
| 52 Week High | $15.90 | $19.57 |
Technical Indicators
Market Signals| Indicator | ETY | ADRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 35.12 |
| Support Level | $13.12 | N/A |
| Resistance Level | $14.79 | $19.01 |
| Average True Range (ATR) | 0.16 | 1.20 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 7.89 | 11.74 |
Price Performance
Historical ComparisonAbout ETY Eaton Vance Tax-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.
About ADRX ADARx Pharmaceuticals Inc. Common Stock
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.